Form 8-K

8-K — BIO-PATH HOLDINGS, INC.

Accession: 0001663577-26-000218

Filed: 2026-07-16

Period: 2026-04-30

CIK: 0001133818

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Unregistered Sales of Equity Securities

Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — bpth_8k071626.htm (Primary)

EX-10.1 — FARRINGTON CAPITAL GROUP, LLC AGREEMENT (ex10_1.htm)

EX-10.2 — ALTFINS, J.S.A. LOI (ex10_2.htm)

GRAPHIC (image_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: bpth_8k071626.htm · Sequence: 1

Bio-Path Holdings, Inc. - Form 8-K - April 30, 2026

false

--12-31

0001133818

2026-04-30

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event

reported): April 30, 2026

BIO-PATH HOLDINGS,

INC.

(Exact name of registrant as specified in its charter)

Wyoming

001-36333

87-0652870

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

625 Stanwix St. #2407, Pittsburgh, PA

15222

(Address of principal executive offices)

(Zip Code)

(630) 708-0750

(Registrant’s Telephone Number, Including Area

Code)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.001 per share

BPTH

OTC Pink

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Bio-Path Holdings, Inc. is referred to herein as “Bio-Path”,

“we”, “us”, or “the Company”.

Item 3.02 Unregistered Sales of Equity

Securities.

On April 30, 2026, under our qualified Tier

1 Regulation A offering, we sold 466,100 common shares to a third-party raising $13,983 in net proceeds. On May 13, 2026, under our qualified

Tier 1 Regulation A offering, we sold 489,200 common shares to a third-party raising $14,676 in net proceeds. We have the capability to

raise an additional $571,341 under the qualified offering though there can be no assurances.

Item 5.03 Amendments to Articles of Incorporation

or Bylaws; Change in Fiscal Year.

On July 14, 2026, our Board of Directors

and Control Shareholder approved the creation of new class of Series B Preferred stock with five million (5,000,000) authorized shares.

Each Series B Preferred share is convertible into 1,000 common shares, votes on an as converted basis, pays no dividends, and has no liquidation

amount above par value of $0.01. A copy of the Series B Certificate of Determination will be made available in early August when stamped

by the Secretary of State of Wyoming in the next 15 days.

Item 7.1 Regulation FD Disclosure

We are in the midst of a strategic turnaround

which may include organically restarting Phase 2 drug trials, assessing the viability of Phase 1 drug trials, partnering, licensing, or

selling our intellectual property, pivoting to blockchain technology to manage and finance our drug discovery trials, raising outside

capital, and/or managing our finances, performing strategic acquisitions and investments to generate growth outside of biotechnology,

and improving our capital structure. There are no assurances that any or all of our efforts will be successful.

Item 8.1 Other Events.

On June 5, 2026, UT MD Anderson cancer center

(“MDA” @ https://www.mdanderson.org/) agreed to restart our Phase 2 trials targeting acute myeloid leukemia (AML) subject

to us bringing them current on monies due of $292,264.21 for BP1001-201-AML and $63,286.55 for BP1002-201-AML. We believe the BP1001-201-AML

Phase 2 trial will remain randomized using MDA to complete the final segment of the trial and can be restarted using a combination of

cash from outside investors under our Tier 1 Regulation A offering and federal grants, which we intend to pursue through consultants.

On June 26, 2026, we opened a business account

with Coinbase Global (NASDAQ: COIN) to manage our recently launched AI-driven digital asset treasury targeting L1 and L2 coins and altcoins.

We intend to allocate up to 50% of capital raised to crypto opportunities.

On July 3, 2026, we engaged Farrington Capital

Group LLC (“FCG” @ https://farringtoncapitalgroup.com/), a strategic advisory firm focused on education, biotech, and real

estate, to identify and close a strategic investor, buyer, JV partner and/or licensor for our biotechnology and intellectual property

including our multiple Phase 1 and Phase 2 drug trials targeting blood cancer, solid tumors, obesity and other domains. We agreed to provide

FCG a 60-day period of exclusivity to move discussions ahead with at least one candidate they have identified. Any fees will be success-based

and there were no shares or cash issued as a retainer. There can be no assurances any transaction will be completed. A copy of the FCS

Agreement is provided herein under Exhibit 10.1.

On July 6, 2026, we issued 22,342 Series

B Preferred shares (subscription payable) for 2,3125,000 Series B Preferred shares and 51 Series M Preferred shares of Himalaya Technologies,

Inc. (OTC: HMLA) valued at $670,260, making HMLA a majority owned subsidiary. HMLA is owner and operator of Mophoe.com @ https://beta.mophoe.com/,

a crypto social site and trading platform currently under development.

On July 6, 2026, we issued 369 Series B Preferred

shares (subscription payable) to our CEO, Vikram Grover, for a software platform that enables the creation of niche social networks including

Kanab Club @ https://www.kanab.club/. We intend to use the code to enhance Mophoe.com and deploy additional communities in the future.

The transaction was valued at $11,069.

On July 14, 2026, our majority owned subsidiary

Himalaya Technologies, Inc. mutually terminated its previously announced strategic development agreement with a third party and canceled

9,684,43 Series B Preferred shares representing one half of the Company’s diluted shares outstanding.

On July 14, 23026, we added Richard Fetyko,

CEO of altFINS, j.s.a. (“altFINS”), a crypto analytics and trading platform @ https://altfins.com/ to our Advisory Board granting

him up to 300,000 stock options over three years with an initial tranche of 100,000 common stock purchase warrants struck at $0.03 subject

to certain adjustments. We intend to add altFINS’ AI driven capabilities to our recently announced Digital Asset Treasury 2.0 (DAT

2.0) to provide excess alpha versus monolithic first generation DAT companies. To this end, we signed a letter of intent (LOI) with altFINS

to partner and cross-invest in each of our Companies, including a planned issuance to altFINS of 2,500,000 common share equivalents (“CSE’s)

in return for an option to buy up to 22% of altFINS equity capitalization for two million euros. We intend to move to definitive agreement

in the next month. A copy of the LOI is provided herein under Exhibit 10.2.

About Farrington Capital Group, LLC:

Farrington Capital Group, LLC (“FCG”)

is a private investment, development, and cognitive holding company that specializes in deploying advanced technology layers across high-impact,

essential industries. Led by Founder and Managing Director Alfred Farrington II, FCG integrates its proprietary “Intelligence OS”

- a technological ecosystem leveraging applied artificial intelligence and blockchain-verified ledgers—to automate operational workflows

and maximize scaling efficiencies across its core portfolio entities. Strategically focused on asset classes within federally designated

Qualified Opportunity Zones, the firm operates at the modern convergence of educational technology, bio-informatics, and localized digital

infrastructure. Through its targeted capital allocation models and deep executive leadership, FCG acts as a modern venture builder, driving

systemic economic development, localized digital access, and high-margin compounding equity growth.

About Richard Fetyko:

Richard Fetyko is the founder and CEO of

altFINS, a crypto analytics and education platform. A 14-year Wall Street veteran, he worked as an equity research analyst at firms including

Janney Montgomery Scott and as a portfolio manager at Twin Capital before founding altFINS in 2020 to bring professional-grade analytical

tools to crypto traders. He holds an MBA in Finance from the University of Oklahoma.

About altFINS, j.s.a.:

altFINS is a crypto analytics and education

platform used by traders worldwide, from beginners to experts, who value data-driven insights over market hype. The platform scans 2,000+

coins across 150 technical indicators, multiple time intervals, and on-chain metrics to deliver automated market insights. Combined with

AI-detected chart patterns, AI trade setups, and expert-vetted analyses, altFINS helps traders find ideas, create alerts, execute strategies,

and monitor portfolio performance across exchanges, turning market noise into confident trading decisions. In 2026, altFINS is expanding

beyond crypto to bring its screening and analysis tools to stocks and forex markets.

Exhibit No. Description

10.1 Bio-Path Holdings, Inc. – Farrington Capital Group, LLC Agreement – 07/03/2026

10.2 Bio-Path Holdings, Inc. – altFINS, j.s.a. LOI – 07/14/2026

104 Cover Page Interactive Data File (embedded

within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned

hereunto duly authorized.

BIO-PATH HOLDINGS, INC.

Dated:

July 16, 2026

By:

/s/ Vikram Grover

Vikram Grover

Chief Executive Officer, Chief Financial Officer and Director

EX-10.1 — FARRINGTON CAPITAL GROUP, LLC AGREEMENT

EX-10.1

Filename: ex10_1.htm · Sequence: 5

NON-BINDING LETfER OF INTENT

Date:

July 3, 2026

To:

Bio-Path Holdings, Inc.

Attn: Vik Grover

From:

Farrington Capital Group LLC.

and/or its

designated affiliate, VantioBio and or Vantio Alpha Fund

Bio-Path

Holdings, Inc. ("Bio-Path")

and Farrington Capital Group LLC. and/or

its designated affiliate, VantioBio and or

Vantio Alpha Fund (collectively,"Buyer") are pleased

to outline the principal terms of

a proposed strategic transaction. This

Letter of Intent is intended to

provide a framework for diligence

and negotiation concerning an exclusive out-license, asset acquisition,

or similar transaction involving

the DNAbilize platform and related Bio-Path programs, studies, data, know-how,

intellectual property, regulatory materials, manufacturing information, and development

documentation.

Transaction

Scope

The

contemplated transaction

would include some or

all of the following,

to the extent owned,

controlled, or licensable

by Bio-Path:

•

Prexigebersen (BP1001), including related

AML studies and supporting materials.

•

BP1001-A, including solid tumor

programs such as ovarian,

endometrial, and pancreatic cancer.

•

BP1001-A obesity and related

metabolic disease applications.

•

BP1002, the liposomal Bcl-2 program.

•

BP1003, the liposomal

STAT3 program.

•

The DNAbilize platform,

including associated patents, patent applications, know-how, formulations,

technical materials, translational materials, regulatory history,

and platform-level supporting

documentation.

•

All BPTH studies

and related preclinical,

clinical, translational, regulatory,

CMC, manufacturing, and data room materials relevant to the covered

assets.

Diligence

and Timing

Upon

execution

of this Letter of

Intent, Bio-Path would

provide Buyer and its advisors

with prompt diligence access to the

covered materials so the

parties can negotiate definitive documentation.

The parties

intend to proceed expeditiously

and use commercially reasonable

efforts to finalize definitive agreements

as promptly as practicable.

Financing

Buyer

has secured a loan

facility and intends

to use such proceeds

as initial capital

for the Vantio Alpha

Fund and related transaction

expenses, subject to final closing

and underwriting requirements.

Any definitive transaction may remain subject to financing and

other customary closing conditions unless otherwise

agreed in writing.

Exclusivity

For

a period of thirty

(30) to sixty

(60) days after execution of this Letter of Intent, Bio-Path will

negotiate exclusively with Buyer

regarding the covered assets and will not solicit,

encourage, or enter into negotiations

with any third party concerning

a competing sale,

license, transfer, or

similar transaction involving the

covered assets or platform rights. This section is

intended to be binding.

Confidentiality, Expenses,

and Governing Law

The

existence and terms of this Letter

of Intent, together with

all non-public information exchanged in connection with

the proposed transaction, will

be treated

as confidential and governed by any

existing confidentiality agreement

between the parties or, if

none exists, a mutually acceptable

confidentiality arrangement.

Each party will bear

its own expenses. This

Letter of Intent will be governed

by the laws of

the State of Florida.

This section is intended

to be binding.

Non-Binding

Effect

Except

for the sections titled

Exclusivity and Confidentiality,

Expenses, and Governing Law, this Letter of Intent

is non-binding and is intended

solely as a basis for further discussion and negotiation.

No binding obligation

with respect to the

proposed transaction

will exist unless

and until definitive agreements are

executed by the parties.

the foregoing is acceptable, please indicate agreement by

signing below.

Accepted

and agreed:

FARRINTON

CAPITAL GROUP LLC.

By:

/s/ Alfred Farrington II

Title:

Business Development & Community Outreach

Date:

July 3, 2026

BIO-PATH

HOLDINGS, INC.

By:

/s/ Vikram Grover

Name:

Vikram Grover

Title:

CEO

Date:

07/08/2026

EX-10.2 — ALTFINS, J.S.A. LOI

EX-10.2

Filename: ex10_2.htm · Sequence: 6

LETTER

OF INTENT – PARTNERSHIP AND INVESTMENT BIO-PATH HOLDINGS, INC. – ALTFINS, J. S. A.

Executive Summary

Bio-Path Holdings, Inc. (OTC: BPTH) and altFINS are exploring

a strategic partnership whereby BPTH establishes a Gen2 digital asset treasury - moving beyond passive Bitcoin accumulation toward a multi-asset,

systematically managed cryptocurrency portfolio informed by altFINS’ institutional-grade on-chain fundamentals and technical analysis.

This proposal outlines the partnership structure, a phased

treasury deployment plan, the speciﬁc altFINS capabilities BPTH would leverage, and how BPTH can differentiate itself from ﬁrst-generation

treasury adopters.

Metric

Value

Public companies holding crypto (mid-2026)

~200+

Collective holdings at peak

$180BN

Market Context: Gen1 vs. Gen2 Treasury Strategies

Early digital asset treasury adopters (Gen1) followed

a simple formula - buy and hold Bitcoin as a reserve asset. MicroStrategy pioneered this; Genius Group (GNS) extended it. While effective

in bull markets, Gen1 strategies suffer from single-asset concentration risk, no systematic entry/exit discipline, and inability to capture

altcoin alpha.

Gen1 cautionary tale

— Genius Group (GNS)

Adopted a Bitcoin-only treasury reserve in late 2024,

targeting 1,000 BTC. Faced court injunctions in early 2025 blocking further purchases and was forced to liquidate its entire 84 BTC position

in April 2026 to clear $8.5MM in debt. Without a systematic investment framework or risk management layer, the strategy was vulnerable

to both regulatory action and balance-sheet stress. GNS is now rebuilding with a broader AI + BTC dual treasury — an implicit move

toward Gen2.

Gen2 template — SRx Health Solutions / SRX

Global

SRx Health (NYSE American: SRXH) began with a 10% cash-ﬂow

allocation to crypto (BTC + ETH + SOL) in mid-2025, then in early 2026 deployed $18M into an "EMJ Gen2" multi-asset model led

by Eric Jackson. The Gen2 framework is explicitly active: it combines on-chain research, position sizing, hedging, and capital rotation

across market cycles — rather than passive accumulation. SRx completed a full corporate

pivot, recently acquiring EMJ Crypto Technologies and CCC Crypto, and rebranded as SRX Global. This is the template BPTH can replicate

at its own scale - without the corporate restructuring and massive dilution.

The BPTH + altFINS partnership is designed to deliver

Gen2 outcomes - active, research-driven, multi-asset treasury management - without requiring BPTH

to build internal crypto expertise from scratch.

Partnership Structure

altFINS provides the data infrastructure, analytical framework,

and ongoing research. BPTH retains full custody and decision authority. The relationship is structured as a data and advisory services

agreement across three layers:

Layer

Name

Description

Layer 1

Data & platform access

BPTH receives perpetual enterprise API access to altFINS' full screener, on-chain fundamentals, and 150+ technical indicators across 2,000+ coins

Layer 2

Research & signals

altFINS delivers curated weekly investment reports, AI-generated trade setups, and chart pattern alerts tailored to BPTH's portfolio criteria

Layer 3

Advisory & governance

altFINS analysts participate in BPTH’s treasury

committee, helping

deﬁne allocation rules, rebalancing triggers,

and risk parameters

How BPTH Would Leverage altFINS

Asset Selection - On-Chain Fundamental Screening

Rather than manually

researching thousands of tokens, BPTH would use altFINS' screener to systematically ﬁlter coins by fundamental on-chain quality

metrics before any technical signal is considered.

Key on-chain fundamentals available via altFINS:

Protocol revenue (daily / 30-day / annualized) and revenue growth rates (7D, 30D, 90D, 180D, 365D),

Total Value Locked (TVL) and TVL momentum - identifying protocols gaining traction,

Market Cap / Sales ratio and Market Cap / TVL ratio - valuation vs. fundamentals,

Circulating supply and fully diluted market cap - assessing inﬂation risk,

CMC rank trajectory - tracking rising vs. falling ecosystem status.

Example screen: coins with annualized protocol revenue

> $10MM, TVL growth > 20% over 90 days, and Market Cap/Sales ratio below sector median - identifying fundamentally sound, undervalued

assets before momentum traders arrive.

Entry Timing — Technical Analysis & AI Signals

Once a coin passes the fundamental screen, altFINS' technical

layer identiﬁes optimal entry

points - reducing the timing risk that destroyed many Gen1

treasuries that bought market tops. Technical tools BPTH would use:

AI Trade Setups - complete entry/stop/target plans for 2,000+ coins, updated continuously,

AI Chart Patterns - automated detection of 26 pattern types (bull ﬂags, cup-and-handle, triangles,

etc.) with up to 84% historical accuracy across 4 timeframes,

Trend conﬁrmation - short/medium/long-term trend scores plus trend change detection signals,

Momentum indicators - RSI (9/14/25), MACD, Stochastic RSI, CCI, ADX, Williams %R, Bull/Bear Power,

Volume analysis - OBV trend, relative volume, VWMA — conﬁrming price moves have

conviction,

Candlestick pattern library - 30+ automated patterns (Hammer, Engulﬁng, Morning Star,

Three White Soldiers, etc.).

Portfolio Construction - Multi-Asset Allocation Framework

BPTH would adopt a structured allocation model, informed

by 2026 institutional best practices and altFINS research:

Tranche

Target Allocation

Assets

Purpose

Core

40–50%

L1’s including BTC, ETH, other

Long-term capital preservation; institutional credibility

Growth

30–40%

Top 20–50 altcoins screened by altFINS fundamentals

Asymmetric upside; sector rotation (DeFi, L1, AI tokens)

Liquidity

15–20%

Stablecoins (USDC, USDT)

Dry powder for dip-buying;

operational ﬂexibility;

yield via

lending

altFINS provides the screener-based watchlist to

continuously populate the Growth tranche with candidates meeting both fundamental and technical criteria.

Risk Management - Systematic Sell Disciplines

Gen1 failures (including GNS) were partly caused by the absence

of systematic exit rules. BPTH would establish altFINS-powered risk triggers:

Trend reversal alerts - medium/long-term trend change signals trigger position

review

ATR-based stop levels - position sizing and stops anchored to each asset's Average True Range

Relative performance monitoring - altcoins underperforming BTC on a rolling 30/90-day basis trigger

rebalancing review

Fundamental deterioration ﬂags - protocol revenue declining >30% over 90 days triggers sell

evaluation regardless of price action

Overbought signals - RSI > 80 combined with bearish candlestick patterns (Shooting

Star, Bearish Engulﬁng) signal proﬁt-taking zones

Reporting & Investor Communications

altFINS provides BPTH with white-label reporting assets

- charts, screener exports, on-chain data summaries - that BPTH can incorporate into quarterly ﬁlings, press releases, and investor

presentations. This positions BPTH’s treasury as transparently managed and data-driven, differentiating it from companies that simply

announce BTC or singular crypto purchases with no analytical framework.

Phased Implementation

Plan

Phase 1 - Q3 2026 (Months 1-2): Foundation

Board approval of digital asset treasury policy with deﬁned allocation parameters,

Execute altFINS enterprise data agreement; integrate API into BPTH treasury workﬂow,

Initial capital deployment into Core tranche (BTC + ETH) using altFINS entry-timing signals to avoid

top-buying,

Publish inaugural Digital Asset Treasury Strategy press release referencing altFINS as data partner.

Phase 2 - Late Q3 2026 - Q4 2026 (Months 3-6): Growth Tranche

Activation

First altcoin positions added from altFINS-screened watchlist (fundamental + technical dual-ﬁlter),

Risk management rules codiﬁed: stop-loss levels, rebalancing triggers, position limits per

asset,

First quarterly treasury performance report published — including on-chain fundamental rationale

for each holding,

Stablecoin liquidity tranche established; explore yield strategies (lending protocols with high TVL

and stable revenue).

Phase 3 - (2027 and Ongoing): Mature Treasury Operations

Active sector rotation - altFINS revenue and TVL trends used to rotate between DeFi, L1, infrastructure,

and AI-token sectors,

Systematic rebalancing back to target allocations on a monthly or signal-triggered basis,

Treasury-as-differentiator narrative for BPTH investor relations - regular altFINS-powered research

updates shared with shareholders,

Evaluate co-branded research publications: "BPTH × altFINS Digital Asset Market Outlook",

Phase 4 – (TBD):

Merger of Altﬁns into BPTH and/or spinout IPO to shareholders.

BPTH Competitive

Differentiation

Most small-cap companies entering the crypto treasury

space in 2026 are still following the Gen1 playbook - announcing BTC purchases with no systematic framework. BPTH’s partnership

with altFINS allows it to position as a data-driven, institutionally managed treasury from day one.

Dimension

Gen1 (typical)

BPTH + altFINS (Gen2)

Asset universe

BTC only

Multi-asset, fundamentally screened

Entry discipline

Ad hoc, market-price buys

Technical signal-timed entries

Exit / risk rules

None or informal

Systematic - trend, ATR, revenue-based

Reporting

"We bought X BTC"

Quarterly on-chain fundamental reports

Research partner

None

altFINS - institutional analytics platform

Investor narrative

Bitcoin reserve play

Systematic digital asset manager

Proposed Commercial Terms

Data & platform license - annual enterprise subscription to altFINS API + screener + AI signals,

Advisory retainer - monthly fee for altFINS analyst participation in treasury committee meetings

and custom research reports,

Co-marketing — mutual press release at partnership launch; joint investor

presentations; altFINS listed as "data and analytics partner"

in BPTH ﬁlings,

Performance alignment (optional) - a small equity or token component tied to treasury AUM growth,

aligning altFINS incentives with BPTH treasury outcomes,

BPTH receives an option to invest up to €2M into altFINS at a €7.4M valuation (pre-money),

altFINS receives 2.5MM shares of BPTH, subject to certain performance deliverables and milestones.

Speciﬁc fee structures are subject to negotiation.

altFINS is open to structuring terms that align with BPTH’s current capital constraints, including deferred or performance-linked

components.

Next Steps

Action

Owner

Timeline

Executive alignment meeting — BPTH board + altFINS leadership

Both

July 2026

altFINS platform demo for BPTH treasury/ﬁnance

team

altFINS

July 2026

Draft treasury policy framework for BPTH board approval

BPTH + altFINS

advisory

August 2026

Legal review and partnership agreement execution

Both legal teams

August 2026

Public announcement and Phase 1 capital deployment

Both

Q3 2026

This non-binding letter of intent (“LOI”)

shall expire on Thursday 07/16/2026 at 5:00pm EDT.

BIO-PATH HOLDINGS, INC.

ALTFINS, J.S.A.

/s/ Vikram Grover

/s/ Richard Fetyko

Vikram Grover

Richard Fetyko

CEO

GRAPHIC

Filename: image_001.jpg · Sequence: 7

Binary file (3899 bytes)

Download image_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Apr. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 30, 2026

Current Fiscal Year End Date

--12-31

Entity File Number

001-36333

Entity Registrant Name

BIO-PATH HOLDINGS,

INC.

Entity Central Index Key

0001133818

Entity Tax Identification Number

87-0652870

Entity Incorporation, State or Country Code

Entity Address, Address Line One

625 Stanwix St. #2407

Entity Address, City or Town

Pittsburgh

Entity Address, State or Province

Entity Address, Postal Zip Code

15222

City Area Code

(630)

Local Phone Number

708-0750

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

BPTH

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name:

dei_CurrentFiscalYearEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:gMonthDayItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration